VX-702

Catalog No.S6005

VX-702 Chemical Structure

Molecular Weight(MW): 404.3

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 110 In stock
USD 370 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Reduction of IL-10 expression due to p38 inhibition is observed also in CpG-stimulated B cells and using VX-702. B cells were pre-treated with 10 uM of VX-702 for 1 h and stimulated with LPS or CpG for 24 or 48 h. Bar graphs indicate mean (±SEM) IL-10 concentrations at 48 h from n = 4 (LPS) and n = 3 (CpG) experiments. Significant differences against the no inhibitor condition were calculated using a paired Student's t-test and indicated as follows: *p < 0.05, ***p < 0.001.

    Mol Immunol 2014 62(2), 266-76. VX-702 purchased from Selleck.

     Bone marrow derived macrophages were pre-treated with the indicated concentrations of VX702 for 1h prior to LPS treatment (100 ng/ml).  TNF-a production was analyzed 24h later.

    Lee lay hoon from National University of Singapore. VX-702 purchased from Selleck.

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.
Features Highly selective, orally active inhibitor of p38 MAPK.
Targets
p38α [1]
(Cell-free assay)
4 nM-20 nM
In vitro

Pre-incubation of platelets with VX-702 (1 μM) completely or partially inhibits p38 activation (IC50 4 to 20 nM) induced by platelet agonists including thrombin, SFLLRN, AYPGKF, U46619 and collagen. VX-702 shows no effect on platelet aggregation induced by any of the p38 MAPK agonists in the presence or absence of anti-platelet therapies. [1] VX-702 inhibits the production of IL-6, IL-1β and TNFα (IC50 = 59, 122 and 99 ng/mL, respectively) in a dose-dependent manner. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HOP-62 cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHnXV2lKdmirYnn0bY9vKG:oIHj1cYFvKEiRUD22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODF3NEOg{txO NYLudYl4W0GQR1XS
human NCI-H720 cell M4HIfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV;CcnFRUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFczOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMEG2PFIh|ryP MkOyV2FPT0WU
JVM-2 cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkCxTY5pcWKrdHnvckBw\iCqdX3hckBLXk1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNFg{KM7:TR?= MnOzV2FPT0WU
human NCI-H69 cell MnjPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIi1XGRKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOlkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB7OUSxJO69VQ>? MmH5V2FPT0WU
human BV-173 cell NXnPSGFQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWnD[WV{UW6qaXLpeIlwdiCxZjDoeY1idiCEVj2xO|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjFzM{i2JO69VQ>? NGjyUVZUSU6JRWK=
human KU812 cell MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn;PTY5pcWKrdHnvckBw\iCqdX3hckBMXThzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVI1QDhizszN MVPTRW5ITVJ?
human DU-145 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGRWNTF2NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVQ2PTRizszN MXXTRW5ITVJ?
KARPAS-45 cell M1\nSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWnsW4lPUW6qaXLpeIlwdiCxZjDoeY1idiCNQWLQRXMuPDViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG0PFI3KM7:TR?= MVPTRW5ITVJ?
human AGS cell Ml3zS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MknTTY5pcWKrdHnvckBw\iCqdX3hckBCT1NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG1NlUyKM7:TR?= MnqzV2FPT0WU
human MOLT-13 cell NYHjbZozT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3e5OWlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OVD2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTV7OEGg{txO M1\jdnNCVkeHUh?=
human NCI-H209 cell NEDyOmNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV7Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkC5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPzV6IN88US=> MUfTRW5ITVJ?
human CTV-1 cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGNVXi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xPFM5QSEQvF2= Mn20V2FPT0WU
LU-139 cell MofTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVfJcohq[mm2aX;uJI9nKGi3bXHuJGxWNTF|OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVk1OzVizszN NEjBWZlUSU6JRWK=
ML-2 cell NWX2ZmF7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkOzTY5pcWKrdHnvckBw\iCqdX3hckBOVC1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNlY3OSEQvF2= NHf2NmtUSU6JRWK=
human K5 cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYHkZVdHUW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlI6OTdizszN M4HGeXNCVkeHUh?=
human SBC-1 cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoTETY5pcWKrdHnvckBw\iCqdX3hckBUSkNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlM3OiEQvF2= MWPTRW5ITVJ?
human COR-L88 cell M{LpSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlzQTY5pcWKrdHnvckBw\iCqdX3hckBEV1JvTEi4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzR6IN88US=> M1;Y[HNCVkeHUh?=
human KY821 cell M3HzWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYjJcohq[mm2aX;uJI9nKGi3bXHuJGt[QDJzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zPVYxOyEQvF2= M1HXRnNCVkeHUh?=
human HCC2218 cell NEj6Uo1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYr2XFFpUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OyNlE5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52OUeyPEDPxE1? Ml7EV2FPT0WU
human ECC10 cell NHHDZo1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWL3OI5LUW6qaXLpeIlwdiCxZjDoeY1idiCHQ1OxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPjV|OEmg{txO NHvicG5USU6JRWK=
human EW-3 cell MnLNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUmzTodNUW6qaXLpeIlwdiCxZjDoeY1idiCHVz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE43PjZzMTFOwG0> M1LTdHNCVkeHUh?=
human EW-18 cell NUTMboJFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGXo[olKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUG4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44PDZ5OTFOwG0> MkLOV2FPT0WU
human UACC-257 cell MkS0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmXrTY5pcWKrdHnvckBw\iCqdX3hckBWSUOFLUK1O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOjB|Mk[g{txO M1\Sc3NCVkeHUh?=
human G-361 cell NHj2cmdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWXJcohq[mm2aX;uJI9nKGi3bXHuJGcuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT60PVUyQSEQvF2= NX3wT2VoW0GQR1XS
human HMV-II cell NYjZOWpPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NE\uZ4xKdmirYnn0bY9vKG:oIHj1cYFvKEiPVj3JTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPzdzOESg{txO MULTRW5ITVJ?
human DEL cell M3r2Rmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYD1VmVTUW6qaXLpeIlwdiCxZjDoeY1idiCGRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlIxPzB2IN88US=> NYTvNHIzW0GQR1XS
human IGROV-1 cell MmC5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUTJcohq[mm2aX;uJI9nKGi3bXHuJGlIWk:YLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlQ{OTh6IN88US=> M4POenNCVkeHUh?=
human SK-OV-3 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVTodY11UW6qaXLpeIlwdiCxZjDoeY1idiCVSz3PWk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi54MU[5O{DPxE1? MnXuV2FPT0WU
human LAMA-84 cell MlzxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M33XN2lvcGmkaYTpc44hd2ZiaIXtZY4hVEGPQT24OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPzF{OESg{txO MojVV2FPT0WU
human NCI-H510A cell NVn4ToE{T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVTyeJlRUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFUyOEFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkmyOVI3KM7:TR?= NUGwN4YzW0GQR1XS
human CP66-MEL cell M4PofWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXXJcohq[mm2aX;uJI9nKGi3bXHuJGNRPjZvTVXMJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk46OzV3OTFOwG0> MlvsV2FPT0WU
human HAL-01 cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEjGXmZKdmirYnn0bY9vKG:oIHj1cYFvKEiDTD2wNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOjd7MUig{txO MUjTRW5ITVJ?
human RS4-11 cell  Mn;DS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH;ScYlKdmirYnn0bY9vKG:oIHj1cYFvKFKVND2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPzB3N{Og{txO NXPsfYZ5W0GQR1XS
human RPMI-8226 cell MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{TEOWlvcGmkaYTpc44hd2ZiaIXtZY4hWlCPST24NlI3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy56MkO3OkDPxE1? NYjIUWRyW0GQR1XS
human NCI-H82 cell NVnKZoh3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUHsbpBLUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFgzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy56OUOwOUDPxE1? NIjkb3lUSU6JRWK=
human NY cells NYS0UotLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnixTY5pcWKrdHnvckBw\iCqdX3hckBPYSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwMke2N|ch|ryP MYHTRW5ITVJ?
human MDA-MB-361 cell NGPWdlRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVzEfI5MUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND60N|E2QCEQvF2= M3S4XHNCVkeHUh?=
human MOLT-4 cell M1r3S2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIrSW2ZKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTlzOUOg{txO NIC0NmJUSU6JRWK=
human DU-4475 cell MmrnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV7xbG5XUW6qaXLpeIlwdiCxZjDoeY1idiCGVT20OFc2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS5yNUW2OUDPxE1? NEPZfVlUSU6JRWK=
human ESS-1 cell Mo\iS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVzJcohq[mm2aX;uJI9nKGi3bXHuJGVUWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT6yPVE4QSEQvF2= NWDldVZHW0GQR1XS
human NCI-H1299 cell NX;pdnh5T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2fXSmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNlk6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS53M{CzN{DPxE1? MmnZV2FPT0WU
human COLO-684 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mmn6TY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[4OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPThzNkWg{txO Mmq1V2FPT0WU
human MV-4-11 cell NX3VVm1OT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYfJcohq[mm2aX;uJI9nKGi3bXHuJG1XNTRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlcyOTl7IN88US=> MljQV2FPT0WU
human D-542MG cell M3H2XGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGQuPTR{TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlM6Ojd{IN88US=> MUDTRW5ITVJ?
human A4-Fuk cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYDJcohq[mm2aX;uJI9nKGi3bXHuJGE1NU[3azDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uOFM3PjJizszN NH3sUoFUSU6JRWK=
human HL-60 cell M4LrUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn3QTY5pcWKrdHnvckBw\iCqdX3hckBJVC14MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuOVIzOTJizszN NH\RSlBUSU6JRWK=
human NCI-H526 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlTOTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEWyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvPTl6MEGg{txO M1PXOnNCVkeHUh?=
human L-363 cell Mn;pS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFXEfI1KdmirYnn0bY9vKG:oIHj1cYFvKExvM{[zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{44QTJ3MjFOwG0> MXzTRW5ITVJ?
human A388 cell NF\KTZVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWjJcohq[mm2aX;uJI9nKGi3bXHuJGE{QDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15LkiwN|g1KM7:TR?= NVG5U|JWW0GQR1XS
human MS-1 M3qzSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHLIXGpKdmirYnn0bY9vKG:oIHj1cYFvKE2VLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23Mlg{PDZ3IN88US=> M2jSOnNCVkeHUh?=
human JAR cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NInvVpdKdmirYnn0bY9vKG:oIHj1cYFvKEqDUjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUeuPFQ6OjNizszN Mkn0V2FPT0WU
human TI-73 cell NUHRNnROT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGfJflZKdmirYnn0bY9vKG:oIHj1cYFvKFSLLUezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PE4xPjJ{IN88US=> MoLkV2FPT0WU
human CTB-1 cell MoPES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVHJcohq[mm2aX;uJI9nKGi3bXHuJGNVSi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OD6xO|gzPSEQvF2= MlThV2FPT0WU
human SK-NEP-1 cell Ml3LS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYjJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU6HUD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVEvOzB|ODFOwG0> MXjTRW5ITVJ?
human HT-29 cell MkTSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVLiXpI{UW6qaXLpeIlwdiCxZjDoeY1idiCKVD2yPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE{NjlzMUGg{txO M2fMZnNCVkeHUh?=
human NCI-H1092 cell MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXXJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUC5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE1NjNzODFOwG0> MUXTRW5ITVJ?
human KMOE-2 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFnH[HBKdmirYnn0bY9vKG:oIHj1cYFvKEuPT1WtNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE1NjZzN{ig{txO NH3EVolUSU6JRWK=
human EM-2 cell MljSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH;XellKdmirYnn0bY9vKG:oIHj1cYFvKEWPLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOU4zQDRzIN88US=> M4SxdnNCVkeHUh?=
human RT-112 cell NGm0bYdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHu3[VNKdmirYnn0bY9vKG:oIHj1cYFvKFKWLUGxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE2NjN7OESg{txO MXXTRW5ITVJ?
human DB cell MlfOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVHRd|VUUW6qaXLpeIlwdiCxZjDoeY1idiCGQjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG1Mlg2OTNizszN NX24fWFSW0GQR1XS
human NCI-H1770 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn7yTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3O|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigQ>? NXXyO4FnW0GQR1XS
human CAL-54 cell MkT3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1[1b2lvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUW0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVYvPzNizszN NHXtTFNUSU6JRWK=
human NB14 cell NGDDSIRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1PDUGlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG3MlY{QTVizszN MYrTRW5ITVJ?
human RPMI-7951 cell M1r3b2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWfJcohq[mm2aX;uJI9nKGi3bXHuJHJRVUlvN{m1NUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVE6NjF5OEOg{txO M3qzbnNCVkeHUh?=
human T47D cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NE[4[FNKdmirYnn0bY9vKG:oIHj1cYFvKFR2N1SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yNU4zOjR|IN88US=> NUXMZpJSW0GQR1XS
human A549 cell NF;GT4VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYDVZZY5UW6qaXLpeIlwdiCxZjDoeY1idiCDNUS5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlEvOjhzMTFOwG0> MWnTRW5ITVJ?
human A2780 cell NGfDdIRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYHJcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MkGuPFIzPSEQvF2= NH;iR2ZUSU6JRWK=
human SK-MEL-24 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2jqfGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVI1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzNwMEOxNUDPxE1? NH33OllUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo The half-life of VX-702 is 16 to 20 hours, with a median clearance of 3.75 L/h and a volume of distribution of 73 L/kg. Both AUC and Cmax values are dose proportional for VX-702, which is predominantly cleared renally. [2] VX-702 (at a dose of 0.1 mg/kg twice daily) has an equivalent effect as that of methotrexate (0.1 mg/kg). In addition, VX-702 (5 mg/kg twice daily) also has an equivalent effect as prednisolone (10 mg/kg once daily), as measured by percentage inhibition of wrist joint erosion and inflammation score. [3] VX-702 selectively inhibits activation of p38 MAPK after ischemia with no effects on ERKs and JNKs. The MI/AAR ratio is significantly reduced in the 50 mg/kg group compared with the 5 mg/kg and vehicle groups.[4]

Protocol

Solubility (25°C)

In vitro DMSO 81 mg/mL (200.34 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 404.3
Formula

C19H12F4N4O2

CAS No. 745833-23-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00395577 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated November 2006 Phase 2
NCT00205478 Completed Rheumatoid Arthritis Vertex Pharmaceuticals Incorporated June 2005 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products

Tags: buy VX-702 | VX-702 supplier | purchase VX-702 | VX-702 cost | VX-702 manufacturer | order VX-702 | VX-702 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID